2015 American Transplant Congress
Pretransplant Elevated Plasma Fibrinogen Level Is Associated With Tumor Recurrence and Poor Prognosis in Hepatocellular Carcinoma Patients After Liver Transplantation
Background and Objective: Elevated plasma fibrinogen (FBG) level is associated with tumor progression and poor patient outcomes in several cancers. The aim of this study…2015 American Transplant Congress
Associations Between Sirolimus Use and Outcomes After Liver Transplant for Hepatocellular Carcinoma
A growing fraction of U.S. liver transplants are being done for the indication of hepatocellular carcinoma (HCC). HCC recurrence after transplant remains a major concern…2015 American Transplant Congress
Predictors of Time to Recurrence and Mortality Associated With Recurrent Hepatocellular Carcinoma After Liver Transplantation
Transplantation, UCLA, Los Angeles, CA.
Background: While recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) portends a poor prognosis, adjuvant therapy may prolong survival. We sought to identify factors that…2015 American Transplant Congress
Recurrence of Hepatocellular Carcinoma After Transarterial Chemoembolization (TACE) Alone and TACE in Combination With Other Treatment Modalities
General Surgery, Houston Methodist Hospital, Houston, TX.
AIM:Treatment of hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) can help downstage tumors prior to orthotopic liver transplantation (OLT); however, there is a risk of…2015 American Transplant Congress
Glomerular Disease (GD) After Kidney Transplant (KTx): Etiologies, Risk Factors and Consequences
1Nephrology, Mayo Clinic, Rochester, MN; 2Pathology, Mayo Clinic, Rochester, MN.
Introduction. Recipients who develop KTx GD may have reduced function and higher risk of graft loss. Using protocol and clinical biopsies we sought to determine…2015 American Transplant Congress
Early Relapse of Atypical HUS Following ABO Incompatible Living Related Paediatric Renal Re-Transplant Successfully Treated With Eculizumab
Background. The female patient presented at 3 years of age with clinical features suggestive of aHUS confirmed genetically as complement factor I mutation (heterozygous for…
- « Previous Page
- 1
- …
- 13
- 14
- 15